Renoprotection by Rosiglitazone in Accelerated Type 2 Diabetic Nephropathy: Role of STAT1 Inhibition and Nephrin Restoration

American Journal of Nephrology

Volumn 32, Issue 2, 2010, Pages 145-155

  Tang, Sydney C W ^a   Leung, Joseph C K ^a   Chan, Loretta Y Y ^a   Cheng, Amy Shan ^a   Lan, Hui Yao ^b   Lai, Kar Neng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOSYLATED ALBUMIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; ROSIGLITAZONE; STAT1 PROTEIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIINFLAMMATORY AGENT; MEMBRANE PROTEIN; PROTECTIVE AGENT; STAT1 PROTEIN, MOUSE;

ABDOMINAL WALL; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLYCEMIC CONTROL; HISTOPATHOLOGY; HOMEOSTASIS MODEL ASSESSMENT; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; SERUM; SIGNAL TRANSDUCTION; SKIN INCISION; UNINEPHRECTOMY; URINE SAMPLING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GLOMERULUS; KIDNEY; METABOLISM; NEPHRECTOMY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; KIDNEY; KIDNEY GLOMERULUS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEPHRECTOMY; PROTECTIVE AGENTS; STAT1 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES;

EID: 77954207147     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000316056     Document Type: Article

References (39)

1. Navarro-Gonzalez JF, Mora-Fernandez C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
2. Tang SC, Leung JC, Chan LY, Tsang AW, Lai KN: Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptorgamma agonist. J Am Soc Nephrol 2006; 17: 1633-1643.
3. Tang SC, Chan LY, Leung JC, et al: Bradykinin and high glucose promote renal tubular inflammation. Nephrol Dial Transplant 2010; 25: 698-710.
4. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65: 116-128.
5. Brenner BM, Cooper ME, de Zeeuw D et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
6. Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-17.
7. Allen TJ, Cooper ME, Lan HY: Use of genetic mouse models in the study of diabetic nephropathy. Curr Atheroscler Rep 2004; 6: 197-202.
8. Breyer MD, Bottinger E, Brosius FC III, et al: Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45.
9. Kume E, Doi C, Itagaki S, Nagashima Y, Doi K: Glomerular lesions in unilateral nephrectomized and diabetic (UN-D) mice. J Vet Med Sci 1992; 54: 1085-1090.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
11. Tang SC, Leung JC, Chan LY, Eddy AA, Lai KN: Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy. Kidney Int 2008; 73: 288-299.
12. Makino H, Miyamoto Y, Sawai K, et al: Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006; 55: 2747-2756.
13. Fukuda M, Nakamura T, Kataoka K, et al: Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. J Hypertens 2010; 28: 340-352.
14. Sarafidis PA, Bakris GL: Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70: 1223-1233.
15. Yang HC, Ma LJ, Ma J, Fogo AB: Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69: 1756-1764.
16. Ninichuk V, Khandoga AG, Segerer S et al: The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007; 170: 1267-1276.
17. Tashiro K, Koyanagi I, Saitoh A, et al: Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2002; 16: 1-4.
18. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80.
19. Okada S, Shikata K, Matsuda M, et al: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52: 2586-2593.
20. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH: Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005; 16: 1711-1722.
21. Banes AK, Shaw S, Jenkins J et al: Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 2004; 286: F653-F659.
22. Ortiz-Munoz G, Lopez-Parra V, Lopez-Franco O et al: Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy. J Am Soc Nephrol 2010; 21: 763-772.
23. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, Marrero MB: High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 2003; 278: 30634-30641.
24. Kumar A, Hawkins KS, Hannan MA, Ganz MB: Activation of PKC-beta(I) in glomerular mesangial cells is associated with specific NF-kappaB subunit translocation. Am J Physiol Renal Physiol 2001; 281: F613-F619.
25. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB: Role of high glucose-induced nuclear factorkappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002; 13: 894-902.
26. Gruden G, Setti G, Hayward A, et al: Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaBdependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 2005; 16: 688-696.
27. Panzer U, Zahner G, Wienberg U, et al: 15-Deoxy-Delta12, 14-prostaglandin J2 inhibits INF-gamma-induced JAK/STAT1 signalling pathway activation and IP-10/CXCL10 expression in mesangial cells. Nephrol Dial Transplant 2008; 23: 3776-3785.
28. Ghosh SS, Gehr TW, Ghosh S, et al: PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 2003; 64: 52-62.
29. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
30. Wendt TM, Tanji N, Guo J, et al: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137.
31. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S: Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104.
32. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
33. Berg UB, Torbjornsdotter TB, Jaremko G, Thalme B: Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM. Diabetologia 1998; 41: 1047-1056.
34. Kanjanabuch T, Ma LJ, Chen J, et al: PPARgamma agonist protects podocytes from injury. Kidney Int 2007; 71: 1232-1239.
35. Benigni A, Zoja C, Tomasoni S, et al: Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptorgamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 2006; 17: 1624-1632.
36. Doublier S, Salvidio G, Lupia E, et al: Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030.
37. Tang S, Leung JC, Abe K, et al: Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003; 111: 515-527.
38. Miceli I, Burt D, Tarabra E, Camussi G, Perin PC, Gruden G: Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol 2010; 298: F381-F390.
39. Miyazaki Y, Cersosimo E, Triplitt C, De-Fronzo RA: Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007; 72: 1367-1373.